Sign In

Login

Password

Forgot Password ? Sign Up

Safinamid (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Safinamid" in German language version.

refsWebsite
Global rank German rank
5doi.org
2nd place
3rd place
3nih.gov
4th place
7th place
2europa.eu
68th place
29th place
2web.archive.org
1st place
1st place
1merckserono.com
low place
low place
1lifepr.de
low place
2,049th place
1morgenpost.de
1,433rd place
86th place
1finanzen.ch
low place
9,791st place
1luks.ch
low place
low place

doi.org

  • Aurélien Lemercier, Yohann Cartigny, Pierrick Morice, Elise Vanbiervliet, Massimiliano Forcato, Gérard Coquerel: Spherical Agglomeration of Safinamide Mesylate: A Case Study of a Simultaneous Control of Crystalline Landscape and Micromeritic Properties in Org. Process Res. Dev. 27 (2023) 669–679, doi:10.1021/acs.oprd.2c00396.
  • Tomasz Pawlak, Marcin Oszajca, Małgorzata Szczesio, Marek J. Potrzebowski: Solid-State Study of the Structure, Dynamics, and Thermal Processes of Safinamide Mesylate – A New Generation Drug for the Treatment of Neurodegenerative Diseases in Mol. Pharmaceutics 19 (2022) 287–302, doi:10.1021/acs.molpharmaceut.1c00779.
  • R. G. Fariello: Safinamide. In: Neurotherapeutics. Band 4, Nr. 1, Januar 2007, S. 110–116, doi:10.1016/j.nurt.2006.11.011, PMID 17199024 (Review).
  • Paolo Pevarello, Alberto Bonsignori, Philippe Dostert, Franco Heidempergher, Vittorio Pinciroli, Maristella Colombo, Robert A. McArthur, Patricia Salvati, Claes Post, Ruggero G. Fariello, Mario Varasi: Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives. In: Journal of Medicinal Chemistry. Band 41, Nr. 4, 1998, S. 579–590, doi:10.1021/jm970599m.
  • Jagadeesh Babu Nanubolu: Conformational Polymorphism in Safinamide Acid Hydrochloride (Z′ = 3 and Z′ = 1) and Observation of a Temperature-Dependent Reversible Single-Crystal to Single-Crystal Phase Transformation of High‑Z′ form (Z′ = 3 ↔ Z′ = 2 via an Intermediate Z′ = 4) in Cryst. Growth Des. 21 (2021) 133–148, doi:10.1021/acs.cgd.0c00958.

europa.eu

ema.europa.eu

finanzen.ch

  • Newron: Safinamide erhält FDA-Zulassung für Parkinson-Krankheit | 21.03.17 | finanzen.ch. In: finanzen.ch. (finanzen.ch [abgerufen am 22. März 2017]).

lifepr.de

luks.ch

merckserono.com

morgenpost.de

nih.gov

ncbi.nlm.nih.gov

  • R. G. Fariello: Safinamide. In: Neurotherapeutics. Band 4, Nr. 1, Januar 2007, S. 110–116, doi:10.1016/j.nurt.2006.11.011, PMID 17199024 (Review).
  • C. Caccia, R. Maj, M. Calabresi, S. Maestroni, L. Faravelli, L. Curatolo, P. Salvati, R. G. Fariello: Safinamide: from molecular targets to a new anti-Parkinson drug. In: Neurology. Band 67, Nr. 7 Suppl 2, Oktober 2006, S. S18–S23, PMID 17030736 (Review).
  • Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E. In: Drugs in R&D. Band 5, Nr. 6, 2004, S. 355–358, PMID 15563241 (Review).

web.archive.org